Chronic myeloid leukemia, version 2.2021

Michael W. Deininger; Neil P. Shah; Jessica K. Altman; Ellin Berman; Ravi Bhatia; Bhavana Bhatnagar; Daniel J. DeAngelo; Jason Gotlib; Gabriela Hobbs; Lori Maness; Monica Mead; Leland Metheny; Sanjay Mohan; Joseph O. Moore; Kiran Naqvi; Vivian Oehler; Arnel M. Pallera; Mrinal Patnaik; Keith Pratz; Iskra Pusic; Michal G. Rose; B. Douglas Smith; David S. Snyder; Kendra L. Sweet; Moshe Talpaz; James Thompson; David T. Yang; Kristina M. Gregory; Hema Sundar

doi:10.6004/jnccn.2020.0047

Chronic myeloid leukemia, version 2.2021

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra PusicMichal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar

Hematology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Original language	English (US)
Pages (from-to)	1385-1415
Number of pages	31
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	10
DOIs	https://doi.org/10.6004/jnccn.2020.0047
State	Published - Oct 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2020.0047

Cite this

Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., Mead, M., Metheny, L., Mohan, S., Moore, J. O., Naqvi, K., Oehler, V., Pallera, A. M., Patnaik, M., Pratz, K., ... Sundar, H. (2020). Chronic myeloid leukemia, version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 18(10), 1385-1415. https://doi.org/10.6004/jnccn.2020.0047

Deininger, MW, Shah, NP, Altman, JK, Berman, E, Bhatia, R, Bhatnagar, B, DeAngelo, DJ, Gotlib, J, Hobbs, G, Maness, L, Mead, M, Metheny, L, Mohan, S, Moore, JO, Naqvi, K, Oehler, V, Pallera, AM, Patnaik, M, Pratz, K, Pusic, I, Rose, MG, Smith, BD, Snyder, DS, Sweet, KL, Talpaz, M, Thompson, J, Yang, DT, Gregory, KM & Sundar, H 2020, 'Chronic myeloid leukemia, version 2.2021', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 10, pp. 1385-1415. https://doi.org/10.6004/jnccn.2020.0047

@article{04f614fbac80407394a327787ccd2a7b,

title = "Chronic myeloid leukemia, version 2.2021",

abstract = "Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.",

author = "Deininger, {Michael W.} and Shah, {Neil P.} and Altman, {Jessica K.} and Ellin Berman and Ravi Bhatia and Bhavana Bhatnagar and DeAngelo, {Daniel J.} and Jason Gotlib and Gabriela Hobbs and Lori Maness and Monica Mead and Leland Metheny and Sanjay Mohan and Moore, {Joseph O.} and Kiran Naqvi and Vivian Oehler and Pallera, {Arnel M.} and Mrinal Patnaik and Keith Pratz and Iskra Pusic and Rose, {Michal G.} and Smith, {B. Douglas} and Snyder, {David S.} and Sweet, {Kendra L.} and Moshe Talpaz and James Thompson and Yang, {David T.} and Gregory, {Kristina M.} and Hema Sundar",

year = "2020",

month = oct,

doi = "10.6004/jnccn.2020.0047",

language = "English (US)",

volume = "18",

pages = "1385--1415",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "10",

}

TY - JOUR

T1 - Chronic myeloid leukemia, version 2.2021

AU - Deininger, Michael W.

AU - Shah, Neil P.

AU - Altman, Jessica K.

AU - Berman, Ellin

AU - Bhatia, Ravi

AU - Bhatnagar, Bhavana

AU - DeAngelo, Daniel J.

AU - Gotlib, Jason

AU - Hobbs, Gabriela

AU - Maness, Lori

AU - Mead, Monica

AU - Metheny, Leland

AU - Mohan, Sanjay

AU - Moore, Joseph O.

AU - Naqvi, Kiran

AU - Oehler, Vivian

AU - Pallera, Arnel M.

AU - Patnaik, Mrinal

AU - Pratz, Keith

AU - Pusic, Iskra

AU - Rose, Michal G.

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Sweet, Kendra L.

AU - Talpaz, Moshe

AU - Thompson, James

AU - Yang, David T.

AU - Gregory, Kristina M.

AU - Sundar, Hema

PY - 2020/10

Y1 - 2020/10

N2 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

AB - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

UR - http://www.scopus.com/inward/record.url?scp=85092265682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092265682&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0047

DO - 10.6004/jnccn.2020.0047

M3 - Review article

C2 - 33022644

AN - SCOPUS:85092265682

SN - 1540-1405

VL - 18

SP - 1385

EP - 1415

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 10

ER -

Chronic myeloid leukemia, version 2.2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this